AI assistant
Clene Inc. — Director's Dealing 2021
Jan 7, 2021
34487_dirs_2021-01-07_3214a034-a7d8-4ecb-b668-1890850aec46.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: Clene Inc. (CLNN)
CIK: 0001822791
Period of Report: 2020-12-30
Reporting Person: Etherington Robert Dee (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 12717.00 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Incentive Stock Option (right to buy) | $0.5039 | Common Stock (428674.00) | Direct | ||
| Incentive Stock Option (right to buy) | $0.144 | Common Stock (1092777.00) | Direct |
Footnotes
F1: This Form 3 amendment is being filed to correct the original Form 3 filed on January 4, 2021. The original Form 3 incorrectly omitted the shares of RDE RX Ventures
LLC, which may be deemed to be beneficially owned by Mr. Etherington.
F2: The securities are owned by RDE RX Ventures LLC. Mr. Etherington is the manager of RDE RX Ventures LLC. The shares owned by RDE RX Ventures LLC may be deemed to be beneficially owned by Mr. Etherington.
F3: Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on November 23, 2015 and currently exercisable. The options expire 10 years from the date of the grant.
F4: Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on July 31, 2014 and currently exercisable. The options expire 10 years from the date of the grant.